Laura Winchester, DPhil, University of Oxford, Oxford, UK, describes the Mapping of Parkinson’s to proteomics consortium, which comprises three different cohorts with three different modalities: brain, blood, and cerebrospinal fluid (CFS) data. Samples were collected from two observational longitudinal cohorts (Oxford Parkinson’s Disease Centre and Tracking Parkinson’s) and the PD Brain Bank. The study aims to find biomarkers by testing and training through machine learning methodology and also includes a validation phase that involves developing signatures related to Parkinson’s disease and its endophenotype disease. Analyzing the refined signatures in the validation cohort found immune response pathways, such as cytokine-cytokine receptors. Dr Winchester’s investigation involved looking at proteomic data. Progression data was also analyzed to see how data changed across timelines in the same cohort. This interview took place at the AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases hosted in Barcelona, Spain.
